All News
Filter News
Found 160 articles
-
Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
6/3/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for three of its wholly-owned investigative therapies, NX-2127, DeTIL-0255 and NX-1607, each currently in Phase 1 development, at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
-
Genentech announced new data related to its investigational CD20xCD3 T-cell engaging bispecific antibody intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
-
Four biotech companies are holding Research-and-Development Day events to present and discuss their pipelines. Here’s a look.
-
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical DevelopmentData to be discussed at Nurix R&D Day at 8:00 a.m. ET today May 26
5/26/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of NX-2127, an orally administered degrader of Bruton’s tyrosine kinase (BTK) with immunomodulatory activity.
-
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas
5/17/2022
Nurix Therapeutics, Inc. announced that the first patient has been dosed in its Phase 1a/1b study to evaluate orally available small molecule NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase in patients with relapsed B-cell malignancies.
-
Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference
5/11/2022
Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18th, 2022 at 11:00 a.m. ET.
-
BioSpace looked at some of the efforts to improve the host system’s immune response, as well as others to improve allogeneic or autologous cell transplants.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update
4/7/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the first quarter ended February 28, 2022 and provided a corporate update.
-
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors
4/5/2022
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs, announced that the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and the lead candidate in its cellular therapy portfolio.
-
Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
4/4/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference.
-
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607
3/29/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, for NX-1607 in the treatment of patients with advanced solid tumors.
-
Nurix Therapeutics to Participate in Upcoming Investor Conferences in March 2022
3/9/2022
Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in March:.
-
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting
3/8/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and DeTIL-0255 clinical programs will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting.
-
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
2/10/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.
-
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update
1/27/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2021 and provided a corporate update.
-
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments
1/25/2022
Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer.
-
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
1/10/2022
Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, outlined key objectives and anticipated milestones for 2022 and provided an overview of recent progress.
-
Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline
1/6/2022
Ambagon Therapeutics today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues.
-
Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix will present an overview of corporate performance in 2021 and major goals for 2022 at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 5:15 pm ET.